The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
The endogenous cannabinoid system protects against colonic inflammation
Open accessAbstract
Excessive inflammatory responses can emerge as a potential danger for organisms' health. Physiological balance between pro- and anti-inflammatory processes constitutes an important feature of responses against harmful events. Here, we show that cannabinoid receptors type 1 (CB1) mediate intrinsic protective signals that counteract proinflammatory responses. Both intrarectal infusion of 2,4-dinitrobenzene sulfonic acid (DNBS) and oral administration of dextrane sulfate sodium induced stronger inflammation in CB1-deficient mice (CB1(-/-)) than in wild-type littermates (CB1(+/+)). Treatment of wild-type mice with the specific CB1 antagonist N-(piperidino-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-pyrazole-3-carboxamide (SR141716A) mimicked the phenotype of CB1(-/-) mice, showing an acute requirement of CB1 receptors for protection from inflammation. Consistently, treatment with the cannabinoid receptor agonist R(-)-7-hydroxy-Delta(6)-tetra-hydrocannabinol-dimethylheptyl (HU210) or genetic ablation of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) resulted in protection against DNBS-induced colitis. Electrophysiological recordings from circular smooth muscle cells, performed 8 hours after DNBS treatment, revealed spontaneous oscillatory action potentials in CB1(-/-) but not in CB1(+/+) colons, indicating an early CB1-mediated control of inflammation-induced irritation of smooth muscle cells. DNBS treatment increased the percentage of myenteric neurons expressing CB1 receptors, suggesting an enhancement of cannabinoid signaling during colitis. Our results indicate that the endogenous cannabinoid system represents a promising therapeutic target for the treatment of intestinal disease conditions characterized by excessive inflammatory responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125 · cited 1×
“bioactive fatty amides, in particular of anandamide (47), and its”
BackgroundSelf-citationThe molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957
Hapten-induced model of chronic inflammation and ulceration in the rat colon
Morris, G. P., Beck, P. L., Herridge, M. S., Depew, W. T., Szewczuk, M. R., & Wallace, J. L. (1989) · Gastroenterology · doi:10.1016/0016-5085(89)90904-9 · Cited by 1,829
Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity
Krawisz, J. E., Sharon, P., & Stenson, W. F. (1984) · Gastroenterology · doi:10.1016/0016-5085(84)90202-6 · Cited by 1,758
The endogenous cannabinoid system controls extinction of aversive memories
Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G., Hermann, H., Tang, J., Hofmann, C., Zieglgänsberger, W., et al. (2002) · Nature · doi:10.1038/nature00839 · Cited by 1,728 · cited 1×
“Eight- to ten-week-old CB1-deficient (CB1–/–) and FAAH-deficient (FAAH–/–) female mice and corresponding wildtype littermates were used for experiments (22, 23).”
MethodSelf-citationCravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R., & Lichtman, A. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161191698 · Cited by 1,310
Self-citationMarsicano, G., & Lutz, B. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00847.x · Cited by 937
Self-citationBrodie, S. E. (1996) · Survey of Ophthalmology · doi:10.1016/s0039-6257(96)80075-0 · Cited by 745
Cited by
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
“Furthermore, they demonstrated that the inflammation was more severe in mice deficient in CB1 receptors than in wild-type mice, whereas genetic ablation of FAAH resulted in protection against this chemically induced colitis (Massa et al., 2004).”
BackgroundPertwee, R. G. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707442 · Cited by 1,935
Psychogios, N., Hau, D. D., Peng, J., Guo, A. C., Mandal, R., Bouatra, S., Sinelnikov, I., Krishnamurthy, R., Eisner, R., Gautam, B., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016957 · Cited by 1,703
The endocannabinoid system and its therapeutic exploitation
Marzo, V. D., Bifulco, M., & Petrocellis, L. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1495 · Cited by 1,090
The Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy Balance
Pagotto, U., Marsicano, G., Cota, D., Lutz, B., & Pasquali, R. (2006) · Endocrine Reviews · doi:10.1210/er.2005-0009 · Cited by 865
Self-citationTargeting the endocannabinoid system: to enhance or reduce?
Di Marzo, V. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2553 · Cited by 798
Organic Carbamates in Drug Design and Medicinal Chemistry
Ghosh, A. K., & Brindisi, M. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501371s · Cited by 739
Cannabinoid-based drugs as anti-inflammatory therapeutics
Klein, T. W. (2005) · Nature Reviews Immunology · doi:10.1038/nri1602 · Cited by 728
Activation of the peripheral endocannabinoid system in human obesity
Engeli, S., Böhnke, J., Feldpausch, M., Gorzelniak, K., Janke, J., Bátkai, S., Pacher, P., Harvey-White, J., Luft, F. C., Sharma, A. M., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.10.2838 · Cited by 686
Structure and function of fatty acid amide hydrolase
McKinney, M. K., & Cravatt, B. F. (2005) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.082803.133450 · Cited by 680
Self-citationEndocannabinoid signaling at the periphery: 50 years after THC
Maccarrone, M., Bab, I., Bíró, T., Cabral, G. A., Dey, S. K., Di Marzo, V., Konje, J. C., Kunos, G., Mechoulam, R., Pacher, P., et al. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.02.008 · Cited by 646
The CB2 receptor and its role as a regulator of inflammation
Turcotte, C., Blanchet, M.-R., Laviolette, M., & Flamand, N. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2300-4 · Cited by 588
Cannabinoids as Novel Anti-Inflammatory Drugs
Nagarkatti, P., Pandey, R., Rieder, S. A., Hegde, V. L., & Nagarkatti, M. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.93 · Cited by 555
“Furthermore, similar to results observed in CB1-deficient mice, pharmacological blockade of CB1 with the specific antagonist SR141716A led to a worsening of colitis [59].”
Enzymatic pathways that regulate endocannabinoid signaling in the nervous system
Ahn, K., McKinney, M. K., & Cravatt, B. F. (2008) · Chemical Reviews · doi:10.1021/cr0782067 · Cited by 529
Self-citationInverse agonism and neutral antagonism at cannabinoid CB1 receptors
Pertwee, R. G. (2005) · Life Sciences · doi:10.1016/j.lfs.2004.10.025 · Cited by 444
Discovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces Inflammatory Pain
Ahn, K., Johnson, D. S., Mileni, M., Beidler, D., Long, J. Z., McKinney, M. K., Weerapana, E., Sadagopan, N., Liimatta, M., Smith, S. E., et al. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.02.013 · Cited by 439
Self-citationEmerging strategies for exploiting cannabinoid receptor agonists as medicines
Pertwee, R. G. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00048.x · Cited by 436
Cannabinoids and the gut: New developments and emerging concepts
Izzo, A. A., & Sharkey, K. A. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.12.005 · Cited by 419
Strasser, F., Luftner, D., Possinger, K., Ernst, G., Ruhstaller, T., Meissner, W., Ko, Y.-D., Schnelle, M., Reif, M., & Cerny, T. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1847 · Cited by 413
Huggins, J. P., Smart, T. S., Langman, S., Taylor, L., & Young, T. (2012) · Pain · doi:10.1016/j.pain.2012.04.020 · Cited by 375
Bioactive lipids, inflammation and chronic diseases
Leuti, A., Fazio, D., Fava, M., Piccoli, A., Oddi, S., & Maccarrone, M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.028 · Cited by 358
Simon, G. M., & Cravatt, B. F. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604660200 · Cited by 356
Self-citationGrundy, D., & Schemann, M. (2005) · Current Opinion in Gastroenterology · doi:10.1097/01.mog.0000153315.28327.6e · Cited by 326
Borrelli, F., Fasolino, I., Romano, B., Capasso, R., Maiello, F., Coppola, D., Orlando, P., Battista, G., Pagano, E., Di Marzo, V., et al. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.01.017 · Cited by 326
The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases
Lowe, H., Toyang, N., Steele, B., Bryant, J., & Ngwa, W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179472 · Cited by 303
WRIGHT, K., ROONEY, N., FEENEY, M., TATE, J., ROBERTSON, D., WELHAM, M., & WARD, S. (2005) · Gastroenterology · doi:10.1016/j.gastro.2005.05.026 · Cited by 299
Endocannabinoids and the regulation of their levels in health and disease
Di Marzo, V., & Petrosino, S. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32803dbdec · Cited by 289
Grundy, D., & Schemann, M. (2007) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e3280287a23 · Cited by 283
Wright, K. L., Duncan, M., & Sharkey, K. A. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707486 · Cited by 264
The Role of the Endocannabinoid System in the Brain–Gut Axis
Sharkey, K. A., & Wiley, J. W. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.04.015 · Cited by 253
The endogenous cannabinoid system and its role in nociceptive behavior
Cravatt, B. F., & Lichtman, A. H. (2004) · Journal of Neurobiology · doi:10.1002/neu.20080 · Cited by 203
Holt, S., Comelli, F., Costa, B., & Fowler, C. J. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706348 · Cited by 168
“Genetic ablation of FAAH also produces protection against intestinal inflammation (Massa et al., 2004).”
BackgroundRegulation of Inflammatory Pain by Inhibition of Fatty Acid Amide Hydrolase
Naidu, P. S., Kinsey, S. G., Guo, T. L., Cravatt, B. F., & Lichtman, A. H. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.164806 · Cited by 108
“Several studies have demonstrated robust anti-inflammatory and antihyperalgesic phenotypes after genetic or pharmacological disruption of FAAH (Cravatt et al., 2001; Lichtman et al., 2004a,b; Massa et al., 2004; Holt et al., 2005), the principal degradative enzyme for anandamide and other bioactive FAAs, but does not…”
BackgroundSelf-citationZhang, D., Saraf, A., Kolasa, T., Bhatia, P., Zheng, G. Z., Patel, M., Lannoye, G. S., Richardson, P., Stewart, A., Rogers, J. C., et al. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.11.009 · Cited by 99
Role of the endocannabinoid system in the regulation of intestinal homeostasis
Cuddihey, H., MacNaughton, W. K., & Sharkey, K. A. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.05.015 · Cited by 79
Nadal, X., La Porta, C., Andreea Bura, S., & Maldonado, R. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.01.077 · Cited by 76
The microbiome and gut endocannabinoid system in the regulation of stress responses and metabolism
Srivastava, R. K., Lutz, B., & Ruiz de Azua, I. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.867267 · Cited by 56
Preclinical science regarding cannabinoids as analgesics: An overview
Lynch, M. (2005) · Pain Research and Management · doi:10.1155/2005/169093 · Cited by 20
“This work supports evidence that CB1 receptors mediate intrinsic protective signals that counteract proinflammatory responses and indicates the endocannabinoid system is a promising target for the treatment of gastrointestinal disorders with excessive inflammatory responses (79).”
Background
Metadata
- Authors
- Massa, F., Marsicano, G., Hermann, H., Cannich, A., Monory, K., Cravatt, B. F., Ferri, G.-L., Sibaev, A., Storr, M., & Lutz, B.
- Venue
- Journal of Clinical Investigation
- Published
- 2004-04-15
- Volume
- 113
- Issue
- 8
- Pages
- 1202-1209
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2131051512
- Cited by
- 460
- References
- 53
- FWCI
- 21.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.